{"product_id":"vani-ansoff-analysis","title":"(VANI) Vivani Medical, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Expansion Decisions with the Full Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Vivani Medical, Inc. Ansoff Matrix Analysis maps the company’s growth options across market penetration, market development, product development, and diversification, showing actionable strategic choices for research, investing, or planning. The page includes a genuine preview\/sample of the analysis so you can review style and substance before buying; purchase the full version to download the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNPM-119 exenatide implant for type 2 diabetes and obesity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivani Medical, Inc.'s NPM-119 targets the huge existing type 2 diabetes and obesity pools, where IDF estimates about 589 million adults live with diabetes and WHO says over 1 billion people live with obesity. The penetration play is simple: win share with a long-acting implant that can cut repeated injections. That keeps Vivani focused on the same demand base, just with a different delivery method.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNPM-115 semaglutide implant for obesity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNPM-115 semaglutide implant is a market penetration play in the large, established obesity drug market, giving Vivani Medical, Inc. a second GLP-1 implant candidate in the same metabolic segment. By using semaglutide, it can compete on convenience and longer treatment persistence versus frequent injections. This also deepens Vivani Medical, Inc.’s presence in obesity, where GLP-1 therapy remains a high-demand, multi-billion-dollar category.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-acting subdermal delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivani Medical, Inc. is targeting the ~50% adherence gap seen in chronic disease care with miniature subdermal implants that can deliver drug steadily for months, which fits patients who miss daily pills. That stable release is the core edge that can support stronger adoption in crowded chronic-therapy markets. If the device keeps dosing predictable, it can turn engineering into repeat use and broader penetration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical-stage U.S. development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVivani Medical, Inc. is still clinical-stage, so market penetration in the U.S. depends on moving its lead implants through human data and FDA steps, not on commercial sales yet. The main share-building lever is stronger clinical proof in obesity, diabetes, and blindness-related programs, because those markets reward clear safety and efficacy data.\u003c\/p\u003e\n\u003cp\u003eIn 2025, the U.S. obesity market alone was still a multibillion-dollar space led by GLP-1 drugs, so even small proof points can matter for future share. This is a pre-commercial push: each study readout lowers risk and improves the case for later adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinical data drives future share.\u003c\/li\u003e\n\u003cli\u003eFDA milestones come before sales.\u003c\/li\u003e\n\u003cli\u003eObesity, diabetes, and eye disease are the targets.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCortigent visual prosthesis for blindness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCortigent gives Vivani Medical, Inc. a second device-led focus in artificial vision, aimed at a massive unmet need: WHO says at least 43 million people are blind. Market penetration will hinge on clinical progress, surgeon and retina-specialist awareness, and fit within the existing blindness-care pathway.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e43 million blind globally\u003c\/li\u003e\n\u003cli\u003eAdoption depends on trial results\u003c\/li\u003e\n\u003cli\u003eClinician awareness will drive use\u003c\/li\u003e\n\u003cli\u003eDevice route, not drug route\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVivani’s Growth Hinges on Trial Wins in Diabetes, Obesity, and Blindness Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVivani Medical, Inc.'s market penetration is still pre-sales, so share gains depend on clinical proof for NPM-119 and NPM-115 in the huge diabetes and obesity pools. The U.S. obesity drug market stayed multibillion-dollar in 2025, and long-acting implants can help lift adherence versus daily or weekly dosing. Cortigent adds a second penetration path in blindness care, but it still needs trial wins and specialist adoption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003e2025-2026 focus\u003c\/th\u003e\n\u003cth\u003ePenetration driver\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNPM-119\u003c\/td\u003e\n\u003ctd\u003eDiabetes, obesity\u003c\/td\u003e\n\u003ctd\u003eFewer injections\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNPM-115\u003c\/td\u003e\n\u003ctd\u003eObesity\u003c\/td\u003e\n\u003ctd\u003eLonger GLP-1 delivery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCortigent\u003c\/td\u003e\n\u003ctd\u003eBlindness care\u003c\/td\u003e\n\u003ctd\u003eClinical and surgeon uptake\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes Vivani Medical, Inc.’s growth strategy through market penetration, market development, product development, and diversification paths\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick Vivani Medical Ansoff Matrix snapshot to simplify growth strategy decisions across products and markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography that validates Vivani Medical’s Ansoff Matrix growth paths for quick due diligence and defensible strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEx-U.S. obesity and diabetes markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivani Medical, Inc. can expand its GLP-1 implant platform outside the U.S. once clinical and regulatory milestones are met, turning an approved metabolic product set into a larger international market. That matters because the International Diabetes Federation estimated 589 million adults had diabetes in 2024, and WHO said obesity topped 1 billion people in 2024. Same product, much bigger patient pool.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty implant centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialty implant centers fit Vivani Medical, Inc. because these products need surgeons and procedural teams, not retail pharmacy shelves. That market development move can open new care channels for its two lead implant programs, including metabolic and vision uses. It also expands access in settings that already handle outpatient implant procedures, where adoption is often faster than in standard drug distribution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEndocrinology referral networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivani Medical, Inc. can grow obesity and type 2 diabetes programs by routing patients through endocrinology-led referrals, keeping the product the same but changing the capture channel. That fits channel-based market expansion: the global diabetes pool reached 589 million adults, and over 1 billion people live with obesity. Endocrinology networks can shorten diagnosis-to-treatment time and lift eligible patient flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBlindness treatment centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVivani Medical, Inc. can take Cortigent’s visual prosthesis into blindness treatment centers to reach a broader institutional buyer pool. That is market development: the same implantable vision tech sold into more specialized clinics that manage severe vision loss, a segment tied to the 2.2 billion people worldwide living with vision impairment or blindness.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew clinic channel, same core implant\u003c\/li\u003e\n\u003cli\u003eTargets severe-vision-loss centers\u003c\/li\u003e\n\u003cli\u003eExpands institutional demand\u003c\/li\u003e\n\u003cli\u003eFits a high-need patient pool\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis route can widen adoption without changing the product, and it matches centers that already treat advanced retinal disease. In the U.S., blindness affects about 1.0 million people, so even small clinic penetration can matter.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHealth-system adoption pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLarge health systems create a new buying path for Vivani Medical, Inc., because one approval can open access across many sites. The U.S. has more than 6,000 hospitals, so institutional protocols, payer review, and specialist workflows can scale the same device into bigger organized care settings. That can turn one implant channel into a system-wide rollout.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne protocol can cover many sites\u003c\/li\u003e\n\u003cli\u003ePayer review can speed broader access\u003c\/li\u003e\n\u003cli\u003eSpecialists can drive repeat adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVivani Medical Can Grow Through New Channels, Not New Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVivani Medical, Inc. can use market development to sell the same implant tech through new specialist channels, not new products. Global demand is large: 589 million adults had diabetes in 2024, over 1 billion people lived with obesity, and 2.2 billion had vision impairment or blindness.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003ePool\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEndocrinology\u003c\/td\u003e\n\u003ctd\u003e589M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVision centers\u003c\/td\u003e\n\u003ctd\u003e2.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eVivani Medical, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNPM-119 exenatide implant\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNPM-119 exenatide implant is one of Vivani Medical, Inc.'s core new products for chronic metabolic disease, aimed at the existing diabetes and obesity markets. By turning exenatide into a long-acting implant, Vivani is shifting from standard drug delivery to a more durable dosing option that could improve adherence. This is classic product development: extend a known therapy into a new format, then move it toward clinical and commercial use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNPM-115 semaglutide implant\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivani Medical, Inc.'s NPM-115 semaglutide implant is a clear product development move: it adds another GLP-1-based candidate to the same metabolic market. The company is extending its implant platform into obesity and diabetes, with semaglutide already a blockbuster class that generated more than $20 billion in annual sales across the market in 2025. This deepens Vivani Medical, Inc.'s line without changing the target market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMiniature implant platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivani Medical’s miniature implant platform centers on tiny, refill-free devices designed to release drug at a steady rate over long periods. Product development here means improving release control, safety, and implant design so dosing stays stable in real use. The same core architecture can be adapted for several therapies, which expands the platform beyond one drug.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eConsistent drug delivery design\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVivani Medical, Inc. treats stable therapeutic delivery as a key device function, so product development is not just about the drug payload. The Ansoff move is product development: improve implant performance, dose control, and release consistency to lift the value of each metabolic asset.\u003c\/p\u003e\n\u003cp\u003eThat matters because tighter delivery can reduce variability in exposure and strengthen clinical utility across the portfolio.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: implant performance\u003c\/li\u003e\n\u003cli\u003eGoal: steadier drug release\u003c\/li\u003e\n\u003cli\u003eEffect: higher product value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCortigent visual prosthesis iterations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCortigent’s visual prosthesis is a separate device line inside Vivani Medical, and product development means iterating a new generation of artificial-vision hardware for blind patients. The platform builds on the earlier Argus II program, which was studied in 30+ patients, and keeps the pipeline focused on making vision signals more usable in daily life.\u003c\/p\u003e\n\u003cp\u003eThat fits Ansoff product development: same medical-device market, but a better product with upgraded performance and usability. Cortigent’s work also adds a distinct device track to Vivani Medical’s pipeline, increasing optionality beyond its core drug-delivery programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSeparate device line\u003c\/li\u003e\n\u003cli\u003eNew generation of vision tech\u003c\/li\u003e\n\u003cli\u003eBuilds on Argus II heritage\u003c\/li\u003e\n\u003cli\u003eTargets blind-patient use value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVivani’s Long-Acting Implants Aim to Redefine Metabolic Drug Delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVivani Medical, Inc. uses product development to upgrade known metabolic drugs into long-acting implants, led by NPM-119 and NPM-115. The aim is better adherence and steadier exposure in the same diabetes and obesity market, where GLP-1 demand was already above $20 billion in 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eUse case\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNPM-119\u003c\/td\u003e\n\u003ctd\u003eNew implant format\u003c\/td\u003e\n\u003ctd\u003eExenatide in diabetes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNPM-115\u003c\/td\u003e\n\u003ctd\u003eNew implant format\u003c\/td\u003e\n\u003ctd\u003eSemaglutide in obesity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCortigent acquisition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivani’s Cortigent acquisition moved it from metabolic implants into visual prosthetics, adding the Orion cortical visual prosthesis program. That is the clearest diversification step in the Ansoff Matrix: a new product category in a new market, not a product tweak. WHO estimates at least 2.2 billion people have near or distance vision impairment, so the addressable need is large.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArtificial vision for blindness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivani Medical, Inc.'s move into artificial vision for blindness is pure diversification: a new market, new product, and new tech stack far outside obesity and diabetes. WHO says at least 1 billion people live with preventable or unaddressed vision impairment, so the need is large. Vivani is pursuing an implantable visual prosthesis, not a drug device, which creates a genuinely new business lane.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharma plus medtech model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivani Medical’s biopharma plus medtech model spans 2 lead implant programs, NPM-115 and NPM-139, while also building the device platform that delivers them. That is broader than a single-therapy biopharma play because it mixes drug development with implantable hardware engineering. Diversification comes from operating in 2 regulatory paths: FDA drug and device oversight.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMetabolic disease and neuroprosthetics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVivani Medical, Inc. now spans 2 distinct markets: chronic metabolic disease and vision restoration. That means different clinicians, different patients, and different buying cycles, so risk is spread across both indication and technology. In Ansoff terms, this is real diversification, not just a bigger product list.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 separate end markets\u003c\/li\u003e\n\u003cli\u003eDifferent clinician groups\u003c\/li\u003e\n\u003cli\u003eDifferent patient needs\u003c\/li\u003e\n\u003cli\u003eDiversified by indication and technology\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTwo-platform company structure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVivani Medical, Inc. uses 2 separate platforms: miniature drug implants and implantable visual prostheses. That split lets each platform serve its own market and grow on its own, so the Company is not tied to 1 therapeutic area. The model adds diversification and can spread pipeline risk across 2 distinct clinical paths.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 platforms, 2 markets\u003c\/li\u003e\n\u003cli\u003eIndependent growth paths\u003c\/li\u003e\n\u003cli\u003eLower single-area risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVivani Expands Into Visual Prosthetics, Broadening Risk and Opportunity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVivani Medical, Inc.'s Cortigent deal is clear diversification: it entered visual prosthetics with the Orion cortical visual prosthesis, a new product in a new market. That spreads risk across 2 separate end markets and 2 clinical paths, while WHO says 2.2 billion people have vision impairment and 1 billion have preventable or unaddressed loss.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew market\u003c\/td\u003e\n\u003ctd\u003eVisual prosthetics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew product\u003c\/td\u003e\n\u003ctd\u003eOrion cortical implant\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeed size\u003c\/td\u003e\n\u003ctd\u003e2.2 billion \/ 1 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235166527753,"sku":"vani-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/vani-ansoff-matrix.webp?v=1785735119","url":"https:\/\/dcfanalyst.com\/products\/vani-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}